Adjuvant Trametinib Delays the Outgrowth of Occult Pancreatic Cancer in a Mouse Model of Patient-Derived Liver Metastasis

PURPOSE: Most patients with pancreatic ductal adenocarcinoma (PDAC) die within 5 years following resection plus adjuvant gemcitabine (Gem) from outgrowth of occult metastases. We hypothesized that inhibition of the KRAS pathway with the MEK inhibitor trametinib would inhibit the outgrowth of occult...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Surg Oncol
Main Authors: Newhook, Timothy E., Lindberg, James M., Adair, Sara J., Kim, Alison J., Stelow, Edward B., Rahma, Osama E., Parsons, J. Thomas, Bauer, Todd W.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5637098/
https://ncbi.nlm.nih.gov/pubmed/26847682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1245/s10434-016-5116-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados